BIOTECH GROWTH N V

BIOTECH GROWTH N V (10% holder) sells 5.78M shares for $12.0M at avg $2.07; stock now $1.88, down 74.6% from 52-week high

BIOTECH GROWTH N V, a 10% owner, executed 7 separate sales totaling 5,784,292 shares on 2025-03-19 for $11,997,749.13, reducing holdings by 67.9% from 8.52M to 2.73M shares. The blended average transaction price was $2.07, while the current market price sits at $1.88, a decline from the sale prices. The stock is down 74.6% from its 52-week high of $7.39, and Black Diamond Therapeutics reported a net loss of $15,557,000.00 over its most recent full fiscal year. This large-scale reduction of a major equity stake in an unprofitable biotech company at prices that have since fallen further, combined with the company's negative earnings trajectory, underscores significant deterioration in company fundamentals between the insider's transaction date and the current market valuation.

10% owner BIOTECH GROWTH N V sells entire 7,879,583-share stake (100% of holdings) for $12,018,409.08

BIOTECH GROWTH N V executed 4 separate sales on 2024-11-01, liquidating its complete 7.88M-share position for $12.0M at a blended average price of $1.53 per share. This represents a full exit by a 10% stakeholder, reducing holdings from 7,879,583 shares to 0 shares post-transaction. The timing is notable: the current price of $1.70 is -84.0% from the 52-week high of $10.65, and the stock has declined -71.8% over the prior 30 days and -62.6% over the prior 90 days. Additionally, ESSA Pharma reported net income of $-7,233,747.00 for its most recent full fiscal year, indicating the company remains unprofitable. The insider's cross-ticker track record shows 3 prior buys with an average 90-day return of -18.5% and a 33.33% win rate, though no same-ticker historical comparison is available to contextualize this specific divestiture against prior EPIX holdings.